You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Clinical Trials Plenary Session<br />
Wednesday, April 20, 2016 9:00 a.m. to 11:00 a.m.<br />
This midday seminar covers important clinical topics identified from other society meetings that affect patient care.<br />
The latest updates within several clinical trials conducted over the course of the last year will be presented with an<br />
open panel discussion at the conclusion.<br />
Moderators<br />
Natalia S. Rost, MD, FAAN<br />
Vice-Chair, AAN Science<br />
Committee<br />
Petra Kaufmann, MD, FAAN<br />
Member, AAN Science<br />
Committee<br />
Ocrelizumab No Evidence of Disease<br />
Activity (NEDA) Status at 96 Weeks in<br />
Patients with Relapsing Multiple Sclerosis:<br />
Analysis of the Phase III Double-Blind,<br />
Double-Dummy, Interferon beta-1a-<br />
Controlled OPERA I and OPERA II Studies<br />
Anthony Traboulsee MD<br />
University of British Columbia<br />
Vancouver, BC, Canada<br />
Efficacy and Safety of<br />
Dichlorphenamide for the Treatment of<br />
Periodic Paralysis: a Phase 3<br />
Randomized, Double-Blind, Parallel-<br />
Group, Placebo-Controlled Trial<br />
James Burge, MD<br />
University College of London<br />
London, United Kingdom<br />
Interim Results from a Phase 2/3 Study<br />
of the Efficacy and Safety of Ex Vivo<br />
Gene Therapy with Lentiviral Vector<br />
(Lenti-D) for Childhood Cerebral<br />
Adrenoleukodystrophy<br />
Florian Eichler, MD<br />
Massachusetts General Hospital<br />
Boston, MA<br />
CODEL (Alliance-N0577;<br />
EORTC-26081/22086; NRG-1071; NCIC-<br />
CEC-2): Phase III Randomized Study of RT<br />
vs. RT+TMZ vs. TMZ for Newly Diagnosed<br />
1p/19q-Codeleted Anaplastic<br />
Oligodendroglial Tumors. Analysis of Patients<br />
Treated on the Original Protocol Design<br />
Kurt A. Jaeckle, MD, FAAN<br />
Mayo Clinic<br />
Jacksonville, FL<br />
Insulin Resistance Intervention After<br />
Stroke (IRIS) Trial: Secondary Stroke<br />
Prevention, Phase 3 Trial<br />
Karen L. Furie, MD, MPH<br />
Rhode Island Hospital/Warren Alpert<br />
Medical School at Brown University<br />
Providence, RI<br />
Wed· April 20<br />
KINECT 3: A Randomized, Double-<br />
Blind, Placebo-Controlled Phase 3 Trial<br />
of Valbenazine (NBI-98854) for Tardive<br />
Dyskinesia<br />
Robert A. Hauser, MD, MBA, FAAN<br />
University of South Florida<br />
Tampa, FL<br />
A 5-HT6 Antagonist as Adjunctive<br />
Therapy to Cholinesterase Inhibitors in<br />
Patients with Mild-to-Moderate<br />
Alzheimer’s Disease: Idalopirdine in<br />
Phase III<br />
Alireza Atri, MD, PhD<br />
California Pacific Medical Center<br />
Research Institute<br />
San Francisco, CA
Change language